Tag Archives: berobenatide

Pfizer Initiates Ph3 Berobenatide OSA Study; Novo Ph3 Zenagamtide Study in Japan; Novo and Anthropic Partner for Drug and AI Development

Three cardiometabolic-related news items have been observed: Pfizer initiated the Ph3 QM berobenatide VESPER-OSA 1 study (view CT.gov record); Novo initiated the zenagamtide AMAZE 10 study in Japanese patients with obesity (view CT.gov record); and Novo and Anthropic entered into a collaboration to accelerate Novo’s drug development and AI-driven software development (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7

A series of cardiometabolic-related news items has been observed from Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, MiniMed, and CSPC Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Innovent QW Oral Small Molecule GLP-1RA Study; Mounjaro CVRR Label Expansion; Pfizer China-Based Berobenatide Obesity Study

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its QW oral small-molecule GLP-1RA (view CT.gov record); Lilly received FDA approval for Mounjaro’s CVRR label expansion based on the SURPASS-CVOT study (view press release); and Pfizer initiated a Ph3 berobenatide study in an obese Chinese population (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ADA 2026 Key Press Releases (June 6)

On the second day of the ADA 2026 conference, nine cardiometabolic-related news items have been observed from Pfizer, Abbott, Novo Nordisk, Hengrui/Kailera Therapeutics, Insulet, Dexcom, MannKind, Biomea Fusion, and Tidepool. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here

Obesity Spotlight Series: Pfizer Eyes Obesity Market Leadership with Questions Still Unanswered

In the eleventh installment of FENIX’s Obesity Spotlight Series, FENIX has conducted an updated deep dive analysis of Pfizer’s current position in the obesity market. Compared to the previous analysis, which was conducted following the April 2025 termination of danuglipron (previous FENIX insight), this updated Spotlight explores key post‑Metsera acquisition questions, including whether the ~$10B price tag was justified, how Pfizer’s oral AOM strategy is positioned, and whether the company can bring its obesity offering to market sooner than anticipated.

This content is for Read Less members only.
Already a member? Log in here

ADA 2026 Preview: Where FENIX will be paying close attention and why

With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.

This content is for Read Less members only.
Already a member? Log in here

New Regeneron Obesity Asset; China-Based Oral GLP-1RA Touts Better Results than Orforglipron; Pfizer’s VESPER-6 Posted

Three cardiometabolic-related news items have been observed: Regeneron posted a Ph1 study of a new obesity asset (view CT.gov record); Vincentage reported positive topline results from the Ph3 obesity study of its oral GLP-1RA (view press release); and Pfizer posted the VESPER-6 study of berobenatide (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here